Company profile for ADARx Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that’s only part of the story. The word “adar” means “wide” or “great” which aptly describes the opportunities for our RNA targeting platform. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver t...
ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that’s only part of the story. The word “adar” means “wide” or “great” which aptly describes the opportunities for our RNA targeting platform. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver transformative precision therapeutics. We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5871 Oberlin Drive, Suite 200 San Diego, CA 92121
Telephone
Telephone
(877) 232-7974
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/07/3183820/0/en/ADARx-Pharmaceuticals-Announces-Positive-Interim-Phase-1-Clinical-Data-for-its-Novel-siRNA-Targeting-Complement-Factor-B-CFB.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/22/3171167/0/en/ADARx-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-3-STOP-HAE-Clinical-Trial-and-Orphan-Drug-Designation-for-ADX-324-a-Long-Acting-siRNA-in-Development-for-the-Prophylact.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/10/20/3169415/0/en/ADARx-Pharmaceuticals-Announces-Clinical-Data-Presentation-at-the-American-Society-of-Nephrology-ASN-Kidney-Week-2025.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/09/17/3151660/0/en/ADARx-Pharmaceuticals-Appoints-Industry-Veteran-Laura-Shawver-Ph-D-as-Board-Chair.html

GLOBENEWSWIRE
17 Sep 2025

https://news.abbvie.com/2025-05-14-AbbVie-and-ADARx-Pharmaceuticals-Announce-Collaboration-and-License-Option-Agreement-to-Develop-Next-Generation-siRNA-Therapies-Across-Multiple-Therapeutic-Areas

PRESS RELEASE
15 May 2025

https://www.globenewswire.com/news-release/2025/01/10/3007733/0/en/ADARx-Pharmaceuticals-to-Present-at-the-J-P-Morgan-43%CA%B3%E1%B5%88-Annual-Healthcare-Conference.html

GLOBENEWSWIRE
10 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty